Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 46

Results For "RNA"

2136 News Found

Zydus Lifesciences announces completion of Phase II(a) clinical trial of Usnoflast
Diagnostic Center | September 11, 2024

Zydus Lifesciences announces completion of Phase II(a) clinical trial of Usnoflast

ALS patients experience neuroinflammation and rapid neurodegeneration


Datopotamab deruxtecan showed median overall survival of 14.6 months in TROPION-Lung01 Phase III trial
Diagnostic Center | September 10, 2024

Datopotamab deruxtecan showed median overall survival of 14.6 months in TROPION-Lung01 Phase III trial

TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population


Aptar Pharma and Pulmotree to develop and promote Kolibri non-propellant liquid inhaler platform
News | September 10, 2024

Aptar Pharma and Pulmotree to develop and promote Kolibri non-propellant liquid inhaler platform

Agreement further expands Aptar Pharma’s leading respiratory portfolio


Aster Health Academy to offer advanced medical courses
News | September 10, 2024

Aster Health Academy to offer advanced medical courses

The collaborations will help curate industry focused courses such as Advanced Certification courses for healthcare professionals in Healthcare Marketing, Healthcare Technology and Specialized Clinical Fellowship Level programs with university accreditation


Combination of ‘Siddha’ drugs reduces anemia in adolescent girls: Study
News | September 10, 2024

Combination of ‘Siddha’ drugs reduces anemia in adolescent girls: Study

The study observed 2,648 girls, of which 2,300 completed the standard 45-day programme


Ifinatamab Deruxtecan continues to demonstrate promising response rates for lung cancer in Phase 2 Trial
Diagnostic Center | September 09, 2024

Ifinatamab Deruxtecan continues to demonstrate promising response rates for lung cancer in Phase 2 Trial

Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients


Lilly and EVA Pharma collaborate to expand access to baricitinib across 49 low- to middle-income countries in Africa
News | September 09, 2024

Lilly and EVA Pharma collaborate to expand access to baricitinib across 49 low- to middle-income countries in Africa

Lilly will license certain baricitinib manufacturing know-how to enable EVA Pharma to manufacture and supply treatment for various immunological diseases


KIMS Hospitals, Hyderabad expands into Kerala
Healthcare | September 07, 2024

KIMS Hospitals, Hyderabad expands into Kerala

The company has entered into a long-term lease and operations and management agreement with Sree Chand Specialty Hospital, situated in Kannur


Nanoform and Celanese collaborate for biologics delivery through small implants
Biotech | September 07, 2024

Nanoform and Celanese collaborate for biologics delivery through small implants

The companies will combine Nanoform’s Biologics platform with the Celanese VitalDose Drug Delivery platform to further optimize controlled release of biologics


National conference on `Universal Access to Health care: Digital Solutions’ at IHC
Digitisation | September 06, 2024

National conference on `Universal Access to Health care: Digital Solutions’ at IHC

The conference aims to bring various stakeholders and experts in the field of healthcare and digital solutions for ensuring ‘universal access to affordable and quality healthcare’